Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
54 hedge funds and large institutions have $4.75M invested in Navidea Biopharmaceuticals Inc. in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
0% more funds holding
Funds holding: 54 → 54 (0)
4% less capital invested
Capital invested by funds: $4.93M → $4.75M (-$180K)
15% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$23.3K |
| 2 |
Citigroup
New York
|
+$14.9K |
| 3 |
Bank of New York Mellon
New York
|
+$14.5K |
| 4 |
PP
PDS Planning
Dublin,
Ohio
|
+$13.4K |
| 5 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
+$9.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$76K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$33.1K |
| 3 |
Jane Street
New York
|
-$24.6K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$23.7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Group One Trading
Chicago,
Illinois
| – | -$5.51K | -737 | -95% |
|
|
TSS
52
Two Sigma Securities
New York
| – | -$5K | -701 | Closed |
|
53
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$5K | -699 | Closed |
|
54
Barclays
London,
United Kingdom
| – | -$7 | -1 | Closed |
|
55
Fifth Third Bancorp
Cincinnati,
Ohio
| – | +$374 | +50 | New |
|
NAVB Hedge Fund Activity: Q1 2018 in Review
54 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2018, worth a combined $4.75M — down 3.7% from $4.93M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NAVB positions and 3 closed out — a net gain of 1 holder — while 11 added to existing stakes and 13 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $23.3K. The largest seller was Sowell Financial Services, cutting an estimated $76K.
- 54 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $4.75M of Navidea Biopharmaceuticals Inc. stock for Q1 2018, down 3.7% quarter-over-quarter.
- 4 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2018 and 3 closed out, a net change of +1 holder.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2018 was Citadel Advisors, an estimated $23.3K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q1 2018 was Sowell Financial Services, an estimated $76K sold.
Based on aggregated 13F filings for Q1 2018.